Compare BioNTech SE - ADR (BNTX) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs PepsiCo, Inc. — how do they compare? BioNTech SE - ADR trades at $90 (market cap $22.86B), while PepsiCo, Inc. trades at $136.75 (market cap $184.87B). The key difference: PepsiCo, Inc. is far larger — about 8.1× BioNTech SE - ADR's market cap, and PepsiCo, Inc. pays a 4.37% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | PEP | |
|---|---|---|
Market Cap | $22.86B | $184.87B |
Sector | Health | Consumer Staples |
52-Week High | $119.34 | $170.44 |
52-Week Low | $83.89 | $133.81 |
Enterprise Value | $6.53B | $227.37B |
Dividend Yield | — | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
PepsiCo (PEP) trades at $136.03, down 1.78% for the day, with a bearish technical signal and mixed sentiment. The stock shows strong profitability with a 10.78% net margin and 51.59% ROE, though revenue growth remains modest. Recent news highlights price adjustments for snacks after consumer pushback on high costs, while analyst consensus leans Hold with a $159.27 price target.
The outlook is cautious near-term due to technical weakness and pricing challenges, but fundamentals support long-term stability. Risks include competitive pressures and margin compression, while opportunities lie in operational improvements and dividend reliability. Investors should weigh current volatility against the company's solid cash flow and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
